The content on this site is intended for healthcare professionals only
Dr Mike Cusnir speaks to ecancer about the updates from ASCO 2021 related to oesophageal and gastric cancers.
He discusses some of the data regarding these cancers and how they can impact the future treatment of oesophageal and gastric cancer.
Watch the meeting in full by following the links below:
Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers
Neoadjuvant PD-1 blockade enables organ preservation in early dMMR tumours without surgery
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer
Nivolumab plus ipilimumab shows superior efficacy in metastatic colorectal compared to nivolumab monotherapy
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
ESMO and WCLC: Latest developments in EGFR mutated NSCLC
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients
